SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors debate whether the current price action signals a sustainable breakout or another temporary pump, with community sentiment sharply divided between long-term believers and vocal skeptics. Discussions are centered on the token's relationship with broader market movements and speculative hopes for future regulatory clarity and institutional adoption.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc is currently seeing significant market activity and high trading volume as investors position themselves ahead of the May 31 PDUFA date for its ADHD treatment, CTx-1301. The community is heavily focused on potential near-term US patent approvals, with many traders drawing comparisons to historical price action following international patent milestones and expressing strong conviction in the stock's long-term commercial potential.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is seeing heightened community engagement as traders react to the stock's high-beta correlation with Bitcoin and its ongoing transition into a crypto-focused treasury company. Discussion is currently polarized, with bulls pointing to the company's Bitcoin holdings and potential for long-term re-rating against net asset value, while bears frequently cite concerns over dilution, reverse splits, and the high costs of operational debt.

GODS token is the currency used in the blockchain-based online trading card game, Gods Unchained. The token will act as a governance so players will be able to decide the development direction of the game. Players can also use the token to mint rare cards. Most importantly, the GODS token will be an integral part of the play to earn concept of the game.

Gods Unchained

Gods Unchained is trending as the community speculates on a potential price breakout, citing its gaming utility and low market capitalization relative to peers as catalysts. Traders are actively debating technical patterns like the cup-and-handle and monitoring for a broader rotation into the gaming sector, with many expressing optimism for long-term growth and high-percentage gains.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors debate whether potential integration into Xs upcoming payment system serves as a long-term catalyst or just a temporary pump. While some community members remain skeptical, citing historical price patterns and bearish sentiment, others are actively loading up on shares in anticipation of a significant breakout.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is seeing significant volatility and high trading volume following the release of promising Phase 1 expansion data for its colorectal cancer treatment, Varsetatug Masetecan. While bulls are energized by positive clinical signals and analyst price target upgrades, the community is actively debating the impact of the newly announced public offering and the long-term dilution risks inherent in clinical-stage drug development.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid a surge in institutional activity, highlighted by a notable streak of daily inflows into newly launched spot ETFs that continues to attract retail attention. Despite ongoing volatility and community debates over its long-term utility versus market speculation, holders remain focused on the potential impact of global regulatory milestones and increased banking partnerships on future liquidity.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the stock sustains bullish momentum, driven by positive analyst upgrades and investor optimism regarding the company's expanding EV lineup and integrated AI chip technology. The community is actively debating the potential for a short squeeze as share prices test major resistance levels, with many long-term shareholders holding firm in anticipation of a significant revaluation.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did RARE Stock Plunge Over 41% Today?

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

Equity

Shares of MoonLake Immunotherapeutics (MLTX) rebounded 14% on Tuesday after a near 90% plunge on Monday.MoonLake on Sunday <a href="https://stocktwits.com/news-articles/markets/equity/moonlake-stock-crashes-premarket-after-sonelokimab-phase-3-data/chDMDY2R37p">announced</a> 16-week results from its late-stage VELA-1 and VELA-2 identical trials of Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS), also known as acne inversa — a chronic inflammatory condition characterized by painful, boil-like nodules that can rupture, drain pus, and leave scars.In VELA-1, Sonelokimab achieved statistical significance for all primary and key secondary endpoints, including a substantial improvement in the disease. However, in VELA-2, the drug failed to achieve statistical significance. Subsequently, on Monday, MLTX closed at $6.25, marking its lowest levels in over three years. The stock is currently trading at $7.41.The mixed data drew several price target cuts. Needham analyst Serge Belanger lowered the firm's price target on MoonLake Immunotherapeutics to $20 from $66 on Tuesday, but maintained a ‘Buy’ rating on the shares. The regulatory path looks uncertain, and MoonLake might need to conduct another late-stage trial in the worst-case scenario, the analyst noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_30_at_1_04_46_PM_png_2ebbe1ed61.webp" alt="MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>MLTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on Sept. 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rise further.<stembedurl>https://stocktwits.com/Leoheart/message/630505115</stembedurl>Another noted that, although analysts have cut price targets, several targets remain higher than current trading levels.<stembedurl>https://stocktwits.com/Freeballin02/message/630504990</stembedurl>Guggenheim also lowered the firm's price target on the stock to $20 from $80 and kept a ‘Buy’ rating on the shares. While investors are now focused on the drug’s regulatory path, the firm noted that MoonLake is conducting multiple clinical studies across other indications, including palmoplantar pustulosis, psoriatic arthritis, and axial spondyloarthritis. These together sum up to a multibillion-dollar market, the firm noted.Citi analyst Samantha Semenkow, meanwhile, downgraded MoonLake Immunotherapeutics to ‘Neutral’ from ‘Buy’ with a price target of $5, down from $72, on "significant" regulatory risk for the drug. The analyst also noted that Moonlake is currently facing financing challenges.MLTX stock is down by 89% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q">AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MoonLake Immunotherapeutics Stock Draws Wall Street Attention Post Monday’s Plunge: Retail Sees Significant Upside

Needham analyst Serge Belanger lowered the firm's price target on the stock to $20 from $66 but kept a ‘Buy’ rating on the shares.

Merck (MRK) and Verona Pharma Plc. (VRNA) on Wednesday announced that the two companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma.Merck will <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/">acquire</a> Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.The purchase price represents a 23.2% upside to Verona ADS’s closing price on Tuesday.VRNA shares were trading 21% higher in the pre-market session at the time of writing.London-based Verona is a biopharmaceutical company focused on respiratory diseases.Through the acquisition, <a href="https://stocktwits.com/symbol/MRK">Merck</a> will add Ohtuvayre to its expanding cardiovascular and pulmonary pipeline and portfolio. Ohtuvayre was approved by the U.S. Food and Drug Administration in 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The drug is also being evaluated in clinical trials for the treatment of non-cystic fibrosis bronchiectasis.Ohtuvayre brought in net sales of $71.3 million for Verona in the first quarter of 2025, marking a growth of 95% from the fourth quarter of 2024.The acquisition, Merck said, is expected to drive growth into the next decade.“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardio-pulmonary diseases while delivering near- and long-term growth as well as value for shareholders,” Merck CEO Robert M Davis said.The transaction, which was unanimously approved by both the Merck and <a href="https://stocktwits.com/symbol/VRNA">Verona Pharma</a> Boards of Directors, is expected to close in the fourth quarter of 2025.On Stocktwits, retail sentiment around Verona jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’ levels.Retail sentiment around Merck, meanwhile, continues to be in the ‘bearish’ territory, accompanied by ‘normal’ message volume.Shares of VRNA have risen 87% this year while MRK shares have declined nearly 18%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dollar-climbs-off-multi-year-lows-as-report-unpacks-bessent-influence-on-tariff-timeline/chFUtg2R5i2">Dollar Climbs Off Multi-Year Lows As Report Unpacks Bessent’s Influence On Trump Tariff Timeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

JDOC
JPMorgan Healthcare Leaders ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest JDOC News

JDOCJPMorgan Healthcare Leaders ETF